Federal charges were filed against two Indian nationals accused of distributing counterfeit pharmaceuticals through a transnational network, following an FDA Office of Criminal Investigations probe announced on Sept. 29.
The case highlights growing vulnerabilities in global pharmaceutical supply chains and the FDA’s cross-border enforcement authority in combating fake medications that pose direct risks to American patients.
Counterfeit pharmaceuticals may contain incorrect active ingredients, wrong dosages or dangerous contaminants, making them a serious patient safety threat, according to the FDA. Details on the specific drugs involved and the defendants’ distribution methods were provided in the agency’s announcement.
The charges resulted from a multi-agency investigation involving the FDA’s criminal enforcement division and the Department of Justice. International law enforcement cooperation was also involved in building the case, the FDA said.
The prosecution underscores the scale of the global counterfeit drug problem. The World Health Organization has estimated that up to 10% of medicines in low- and middle-income countries are substandard or falsified, and the problem increasingly affects higher-income countries as online pharmaceutical sales grow.
Americans are exposed to counterfeit drug risks through online pharmacies, cross-border mail-order purchases and, in some cases, infiltration of the legitimate U.S. drug supply chain. The FDA’s Office of Criminal Investigations conducts hundreds of cases annually targeting drug counterfeiting, diversion and fraud.
The case also reflects the FDA’s expanding international enforcement footprint. The agency maintains offices in several countries and works with foreign regulatory authorities to intercept counterfeit products before they reach American consumers.
If convicted, the defendants face significant federal prison sentences. The case is being prosecuted by the Department of Justice.